Results 131 to 140 of about 3,204,397 (250)
Background: Multi-drug resistant tuberculosis impairing the effectiveness of standard treatments may contribute to increased mortality. High failure and relapse rates are recorded when standard regimens are used for multi-drug resistant tuberculosis ...
core
Endothelin receptor type A (EDNRA) and the Hippo/YAP pathway form a self‐reinforcing loop that sustains triple‐negative breast cancer. EDNRA activates YAP through Gαq/11–Rho/ROCK–LATS signaling, while YAP/TEAD4 reciprocally drives EDNRA transcription.
Zehao Hong +10 more
wiley +1 more source
Corramycin, a myxobacterial natural product antibiotic, exhibits potent bactericidal activity against multidrug‐resistant Mycobacterium tuberculosis. The compound hijacks bacterial transporters such as BacA and OppABCD to enter the cell and inhibits DNA synthesis through a previously unrecognized mode of DNA gyrase poisoning, locking the enzyme in an ...
Franziska Fries +25 more
wiley +1 more source
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu +18 more
wiley +1 more source
Extensively drug-resistant tuberculosis: epidemiology and management
Alberto Matteelli,1 Alberto Roggi,1 Anna CC Carvalho21Institute of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-Infection, University of Brescia, Brescia, Italy; 2Laboratory of Innovations in Therapies, Education and ...
Roggi A, Carvalho ACC, Matteelli A
core
Resolution pharmacology is an emerging strategy to tackle inflammatory pathologies. Bioinspired meroterpenoids induce a lipid mediator class switch toward inflammation resolution in vitro and in vivo by targeting key nodes in lipid mediator biosynthesis and neutral lipid dynamics.
Lorenz Waltl +20 more
wiley +1 more source
Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan +9 more
wiley +1 more source
Rhoifolin directly targets NMNAT1, thereby activating nicotinamide salvage pathway and promoting intracellular NAD+ biosynthesis. Elevated NAD+ levels enhance SIRT1 activity, leading to FOXO1 deacetylation and nuclear translocation. Nuclear FOXO1 subsequently binds to the IL‐22 promoter, upregulating IL‐22 transcription and potentiating ILC3 effector ...
Hongqiong Yang +12 more
wiley +1 more source
Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier +16 more
wiley +1 more source
VEGFR‐2 signaling in OSCC activates Src–STAT6‐dependent CSF2 transcription, driving tumor‐derived GM‐CSF secretion. GM‐CSF programs neutrophils to express PD‐L1 through STAT5–mTOR/S6K signaling, suppressing cytotoxic CD8+ T cells. This pathway reveals a tumor–neutrophil immune checkpoint circuit that limits anti‐PD‐1 responsiveness in OSCC.
Fangxing Zhu +13 more
wiley +1 more source

